comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 06:02:23 - browse：1

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： CVS Caremark has created a new ploy: the drug ‘rebate credit’

explore

WSS

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Health AI adoption puts security, privacy startups on investors' radar

5 to watch: Tech startups trying to solve health care's staffing crisis

Phenylephrine and the overlooked value of the placebo effect

Stroke deaths set to near 10 million globally by 2050

Baby aspirin cuts fat buildup in liver disease patients, in small study

leisure time

comprehensive

explore

Virginia high school admissions case could be legal follow

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Dobbs anniversary: the lost opportunity of abortion as health care

Why Charlie Gard's case is so disturbing to Americans

Peter Hotez and the public health issue of online harassment

VC firm General Catalyst wants to buy a health system

DIEP, the 'gold standard' of breast reconstruction, is under threat

Asbestos, a deadly carcinogen, banned by EPA

Continuity nursing helped my family in our darkest PICU moments

FDA authorizes Novavax’s updated Covid

knowledge

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Histogen: Failed biotech offers rare public look inside

Was Amgen transparent enough on FDA's concern on cancer drug?

Positive childhood experiences can help future health

Methadone treatment changes are coming. Do they go far enough?

SCOTUS questions limit to govt efforts to fight misinformation

knowledge

explore

explore

hotspot